Systemic sclerosis: demographic, clinical and serological features in 100 Iranian patients

[1]  U. Müller-Ladner,et al.  Pulmonary arterial hypertension in systemic sclerosis. , 2010, Autoimmunity Reviews.

[2]  T. Mimori,et al.  Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay. , 2009, Rheumatology.

[3]  C. Denton,et al.  A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. , 2009, Rheumatology.

[4]  Torsten Witte,et al.  Autoantibody Detection Using Indirect Immunofluorescence on HEp‐2 Cells , 2009, Annals of the New York Academy of Sciences.

[5]  D. Huscher,et al.  Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort , 2009, Arthritis research & therapy.

[6]  M. Koenig,et al.  Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. , 2008, Autoimmunity reviews.

[7]  M. Fritzler,et al.  Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes , 2007, Arthritis research & therapy.

[8]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[9]  O. Meyer.  Prognostic markers for systemic sclerosis. , 2006, Joint, bone, spine : revue du rhumatisme.

[10]  John D Reveille,et al.  Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. , 2003, Arthritis and rheumatism.

[11]  A. Wiik,et al.  The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. , 2003, Rheumatology.

[12]  Y. Ikeda,et al.  Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases , 2002, Annals of the rheumatic diseases.

[13]  Daniel H Solomon,et al.  Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. , 2002, Arthritis and rheumatism.

[14]  S. Bombardieri,et al.  Systemic Sclerosis: Demographic, Clinical, and Serologic Features and Survival in 1,012 Italian Patients , 2002, Medicine.

[15]  M. Alavi,et al.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis , 2002, Annals of the rheumatic diseases.

[16]  C. Denton,et al.  Anti-fibrillarin antibodies in systemic sclerosis. , 2001, Rheumatology.

[17]  P. Maddison.  Mixed connective tissue disease: overlap syndromes. , 2000, Bailliere's best practice & research. Clinical rheumatology.

[18]  Sato,et al.  Distribution and antigen specificity of anti‐U1RNP antibodies in patients with systemic sclerosis , 1999, Clinical and experimental immunology.

[19]  G. Komatireddy,et al.  Analysis of autoantibodies against RNA polymerases using immunoaffinity-purifed RNA polymerase I, II, and III antigen in an enzyme-linked immunosorbent assay. , 1998, Clinical immunology and immunopathology.

[20]  K. Flaherty,et al.  African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. , 1998, Chest.

[21]  S. Ullman,et al.  Mortality and causes of death of 344 Danish patients with systemic sclerosis (scleroderma) , 1998, British journal of rheumatology.

[22]  N. McHugh,et al.  Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. , 1997, The Journal of rheumatology.

[23]  W. Earnshaw,et al.  Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. , 1994, Arthritis and rheumatism.

[24]  T. Medsger,et al.  Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis , 1993, Annals of Internal Medicine.

[25]  D. Bloch,et al.  Predictors of survival in systemic sclerosis (scleroderma). , 1991, Arthritis and rheumatism.

[26]  G. Reimer,et al.  Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). , 1988, Arthritis and rheumatism.

[27]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[28]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[29]  T. Medsger,et al.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. , 1986, Arthritis and rheumatism.

[30]  E. Tan,et al.  Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. , 1982, Clinical and experimental immunology.

[31]  P. Grenier,et al.  Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. , 2006, Arthritis and rheumatism.

[32]  M. Mayes.  Scleroderma epidemiology. , 2003, Rheumatic diseases clinics of North America.

[33]  C. Denton,et al.  Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. , 1998, British journal of rheumatology.

[34]  V. Steen,et al.  Autoantibodies in systemic sclerosis. , 1996, Bulletin on the rheumatic diseases.

[35]  M. Kuwana,et al.  Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. , 1994, Arthritis and rheumatism.

[36]  T. Medsger,et al.  Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. , 1992, Arthritis and rheumatism.

[37]  S. Whittingham,et al.  Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. , 1989, Arthritis and rheumatism.